Tenofovir-associated Fanconi Syndrome in patients with chronic hepatitis B monoinfection
|
|
- Rafe Conley
- 6 years ago
- Views:
Transcription
1 This PDF is for personal use only. To obtain commercial reprints, Tenofovir-associated Fanconi Syndrome in patients with chronic hepatitis B monoinfection David M Gracey, Paul Snelling, Paul McKenzie, Simone I Strasser Antiviral Therapy 2013; /IMP2649 Submission date 15th April 2013 Acceptance date 8th May 2013 Publication date 10th July 2013 This provisional PDF matches the article and figures as they appeared upon acceptance. Copyedited and fully formatted PDF and full text (HTML) versions will be made available soon. For information about publishing your article in Antiviral Therapy go to International Medical Press ISSN
2 Case report Publication: Antiviral Therapy; Type: Case report Tenofovir-associated Fanconi Syndrome in patients with chronic hepatitis B monoinfection David M Gracey 1,2 *, Paul Snelling 1, Paul McKenzie 2,3, Simone I Strasser 2,4 1 Renal Unit, Royal Prince Alfred Hospital, Sydney, Australia 2 Central Clinical School, Faculty of Medicine, University of Sydney, Sydney, Australia 3 Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia 4 AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, Australia *Corresponding author david.gracey@sswahs.nsw.gov.au Abstract Tenofovir disoproxil fumarate (TDF) is increasingly used in patients with chronic hepatitis B (CHB) infection. Although associated with renal toxicity in HIV-infected patients, renal dysfunction has been reported rarely in the monoinfected CHB population. To date, TDF-associated Fanconi Syndrome has not been reported. Here we present two cases of TDF-associated Fanconi Syndrome with rapid resolution after its cessation. We then discuss risk factors for TDF nephrotoxicity and its implications for screening for renal disease in those patients with CHB monoinfection on TDF, and the use of TDF in at risk populations. Accepted 8 May 2013, published online 10 July 2013 Introduction This PDF is for personal use only. To obtain commercial reprints, Tenofovir disoproxil fumarate (TDF) is a highly effective antiviral nucleotide analogue reverse transcriptase inhibitor (NRTI), which is active against both human immunodeficiency virus (HIV) and hepatitis B virus (HBV) [1]. Tenofovir was approved by the United States Food and Drug Administration for the treatment of HIV in 2001 and for chronic hepatitis B (CHB) monoinfection in 2008 and is recommended in international guidelines as a first line agent for treatment-naïve CHB patients, as well as in those patients with treatment emergent drug resistance [2 5] TDF is also effective in treating CHB in patients co-infected with HIV and in HBV-positive solid organ transplant recipients [6,7]. Amongst the HIV-infected patient population treated with TDF, nephrotoxicity has been reported, although is uncommon, with 1-2% of patients affected [8]. Renal dysfunction has also been seen in CHB patients co-infected with HIV [6]. The most prominent renal toxicity is proximal renal tubular dysfunction and, in some cases, the Fanconi Syndrome. The Fanconi Syndrome is characterized by a global dysfunction of the proximal renal tubule, leading to an excess urinary
3 Publication: Antiviral Therapy; Type: Case report excretion of solutes handled by the proximal tubule, such as phosphate, glucose and bicarbonate. It manifests clinically with acidosis, electrolyte imbalances and osteomalacia [9]. If severe, these features may be life-threatening. To date, renal toxicity has been reported rarely in ongoing registration studies of TDF in CHB moninfection [10]. However, up to 15% of monoinfected CHB patients treated with adefovir (ADF) or TDF or both developed proximal renal tubular dysfunction, defined by the de novo appearance of at least three clinical features of the Fanconi Syndrome, in one small study [11]. Dose-dependant nephrotoxicity of TDF has also been demonstrated in animal studies [12]. The Fanconi Syndrome has not been reported in HBV monoinfected patients. Here we report two cases of the Fanconi Syndrome in patients undergoing treatment with TDF for CHB monoinfection. We then discuss the implications of these cases for the screening and management of monoinfected CHB patients on TDF, focusing on groups at risk of nephrotoxicity and current guidelines. Cases This PDF is for personal use only. To obtain commercial reprints, A 39-year-old male of South East Asian descent with CHB was referred to the renal service because of progressive renal impairment. He was a participant in a phase 3 clinical trial evaluating the safety and efficacy of TDF in patients with HBeAg negative CHB (GS-US ), and was randomized to the comparison arm of ADF 10mg daily for 48 weeks before switching to open-label treatment with TDF 300mg daily for up to 7 years. At study entry, his HBV DNA level was 110,000 IU/ml and liver biopsy revealed mildly active chronic hepatitis (Metavir score A1 F1). In addition to CHB, he also had hypertension, controlled with telmisartan, but had no other co-morbidities and no known history of renal disease. Before commencing TDF the serum creatinine was 95 mol/l and the egfr 81 ml/min/1.73m 2. At the time of switching to TDF 48 weeks later the serum creatinine was 96 mol/l, egfr 80 ml/min/1.73m 2. After commencing TDF, there was a slow increase in his serum creatinine level to a peak of 150 mol/l; egfr 46 ml/min/1.73m 2 (Fig 1a). Hepatitis B virus DNA fell from 45,000 IU/mL at the time of commencing TDF, and was undetectable within 15 months of TDF treatment. At his initial renal review 48 months after commencing TDF, the serum creatinine was 127 mol/l and egfr 59 ml/min/1.73m 2. At that time he was receiving marketed TDF having completed the clinical trial, and having elected not to participate in a follow-on study. He never reached a level of creatinine or creatinine clearance to stop or reduce treatment while enrolled in the clinical trial. At full renal evaluation he had low-grade proteinuria (0.6 g/24 hours) but no microhematuria. He had a persistently low serum uric acid level (0.21 mmol/l) and glycosuria. A renal biopsy was undertaken while he was still taking TDF, and demonstrated evidence of proximal tubular injury (Fig 2a) with abundant granular cytoplasm and reactive nuclear enlargement (Fig 2b). Electron microscopy
4 Publication: Antiviral Therapy; Type: Case report confirmed abundant giant mitochondria (Fig 2c), as reported in HIV-infected patients with TDFassociated Fanconi Syndrome [8]. The patient was subsequently switched to entecavir 0.5mg daily with a slow, sustained improvement in his renal function (see figure 1) and a normalization of his serum uric acid, as well as a disappearance of his proteinuria. At his last review over 24 months since ceasing TDF, the serum creatinine had not returned to the normal range (117 mol/l; egfr 64 ml/min/1.73m 2 ), meaning a loss of 16 ml/min/1.73m 2 of egfr since he had been treated with TDF. He had no features of proximal renal tubular dysfunction. The second patient was referred for renal assessment in February 2012 because of renal dysfunction (fig 1b). He was a 54-year-old man of Mediterranean heritage; he had been on TDF 300mg daily for HBeAg-negative CHB for 24 months. His initial HBV DNA level was 6,400,000 IU/mL and was undetectable by 12 months of TDF treatment. A liver biopsy performed in 2010 demonstrated mild active hepatitis, but no fibrosis (Metavir score A1 F2). He was overweight with a history of dyslipidemia, borderline hypertension not on medical therapy, and had mild obstructive sleep apnea. In the 2 years prior to commencing TDF his serum creatinine was intermittently elevated, but was normal (94 mol/l) on the day TDF was commenced and the egfr was 77 ml/min/1.73m 2. At that time he did not have proteinuria or haematuria. On initial review by the renal physician the serum creatinine was 135 mol/l and egfr 51ml/min/1.73m 2. He had aminoaciduria, glycosuria, low-grade proteinuria (0.2 g/24 hours), hypophosphataemia (0.68 mmol/l) and hypouricaemia (0.08 mmol/l). He had an elevated 24-hour phosphate excretion. This presentation was consistent with TDF-associated Fanconi Syndrome, and he was subsequently switched to entecavir 0.5mg daily. Given the distinct clinical features, a renal biopsy was not undertaken and a trial of TDF cessation was undertaken. Three months after ceasing TDF and switching to entecavir, the serum creatinine had fallen to 106 mol/l and the egfr was 67 ml/min/1.73m 2. His proteinuria and hypophosphataemia had also completely resolved. At his last review, over 18 months since ceasing TDF the serum creatinine was 108; egfr 66 ml/min/1.73m 2, meaning a loss of 10ml/min/1.73m 2 of egfr since he had been treated with TDF. He had no features of proximal renal tubular dysfunction. Discussion This PDF is for personal use only. To obtain commercial reprints, This is the first report of tenofovir-associated Fanconi Syndrome in HBV monoinfection. This report highlights that not only patients with HIV or HIV-HBV coinfection, but also patients with HBVmonoinfection are at risk for this potentially severe complication of TDF therapy. However, data to date suggest that nephrotoxicity is less evident in HBV monoinfection [13]. As well, the estimated reduction in glomerular filtration rate was less in the HBV monoinfected population when compared to the HIV monoinfected population in one study [14]. In the European cohort study of tenofovir in HBV monoinfection, the proportion of patients with an egfr <50ml/min remained stable throughout the study [15].
5 Publication: Antiviral Therapy; Type: Case report Risk factors for the development of TDF-associated nephrotoxicity have been identified in HIVinfected patients, although not all patients have identifiable risk factors. Risk factors include increased age, pre-existing renal impairment, concomitant use of nephrotoxic medications, co-morbidities such as diabetes and hypertension, and use of some protease inhibitors [5]. In the patients reported here, the first patient had prior treatment with ADF, an antiviral agent recognized for nephrotoxicity [16], which may have predisposed him to developing TDF- associated renal damage. He was also known to have hypertension and borderline renal impairment. The second patient also had pre-existing mild renal impairment, possibly related to long-standing mild hypertension. In treatment-naïve patients with CHB who have evidence of pre-existing renal impairment, TDF may not be an ideal choice of antiviral agent and perhaps entecavir should be recommended. In treatment-experienced patients, it may still be the best choice of agent as, to date; no TDF-associated antiviral drug resistance has been reported. Patients undergoing long-term treatment with TDF should be monitored in order to detect renal dysfunction. The HIV Medicine Society of the Infectious Diseases Society of America has recommended that patients who are receiving TDF be screened at least every 6 months for egfr, serum phosphate, proteinuria and glycosuria [17]. Three monthly testing in the initial year of therapy has also been suggested [8]. The European Society for the Study of the Liver (EASL) recommends monitoring with serum creatinine (estimated creatinine clearance) and serum phosphate levels in all patients with CHB undergoing treatment with adefovir or tenofovir. They recommend monitoring every 3 months in the first year and 6 monthly thereafter, with more intense monitoring in those with high renal risk or development of renal dysfunction [4]. Practice guidelines form the American Association for the Study of the Liver (AASLD) [3] and the Asia Pacific Association for the Study of the Liver (APASL) [18] are less specific. Nephrotoxicity may develop in patients without obvious risk factors for TDF-associated pathology and may be seen at variable times after the commencement of therapy; hence, it is important that all patients placed on a TDF-containing antiviral regimen be carefully monitored [8]. If significant abnormalities are detected, and there is an effective alternative agent, TDF treatment should be stopped. Apart from adjustment of dosage according to creatinine level, there are no current recommendations for patients with multi-drug resistance who require tenofovir because of lack of availability of a suitable alternative agent. Disclosure statement SIS is a clinical investigator and member of hepatitis B scientific advisory boards for Gilead Sciences and Bristol-Myer Squibb. References This PDF is for personal use only. To obtain commercial reprints, 1. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine and efavirenz for HIV. N Engl J Med 2006; 354:
6 This PDF is for personal use only. To obtain commercial reprints, Publication: Antiviral Therapy; Type: Case report 2. Yuen M, Lai C. Treatment of chronic hepatits B: Evolution over two decades. J Gastroenterol Hepatol 2011; 26 Suppl. 1: Lok AS, McMahon BJ. Chronic hepatitis B: Update Hepatology 2009; 50: European Association For The Study Of The Liver. Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008; 2: Ratcliffe L, Beadsworth M, Pennell A, et al. Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients. AIDS 2011; 25: Daude M, Rostaing L, Saune K, et al. Tenofovir therapy in hepatitis B virus-positive solid-organ transplant recipients. Transplantation 2011; 91: Hall AM, Hendry BM, Nitsch D, et al. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 2011; 57: Fanconi G. Der Fruhenfantile nephrotisch-glykosurische zergwuchs mit hyperphostamischer rachitis. Jahrb. Kinderheilkd. 1936; 147: Fontana R. Side effects of long-term oral antiviral therapy for Hepatits B. Hepatology 2009; S185 S Gara N, Zhao X, Collins MT, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther 2012; 35: Van Rompay KKA, Durand-Gasselin L, Brignolo LL, et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 2008; 52: Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in real life settings: from clinical trials to clinical practice. Viral Hep 2012; 19: Mauss S, Berger F, Filmann N, et al. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol 2011; 55: Lampertico P, Soffredini R, Vigano M et al. 2 year effectiveness and safety of tenofovir in 302 NUCnaïve patients with chronic hepatits B: a multicentre European study in clinical practice. Hepatology. 2011;54(Suppl 1): Abstract Izzedine H, Hulot JS, Launay-Vacher V, et al. renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two doubleblind, randomized, placebo controlled studies. Kidney Int 2004; 66: Gupta SK, Eustace JA, Winton JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40: Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008; 2: Figure 1: Serum creatinine ( mol/l) and serum phosphate (mmol/l) before and after cessation of Tenofovir in case 1 (Fig 1a) and case 2 (Fig1b). Figure 2: Renal biopsy findings in case 1. Haematoxylin and eosin x10 (fig 2a) Haematoxylin and eosin x40 (fig 2b) and electron microscopy (fig 2c). The light microscopic findings were of prominent proximal tubular abnormalities with large eosinophillic inclusions on high power. The electron microscopy demonstrated abnormal giant mitochondria, as reported in in HIV-infected patients with tenofovirinduced nephrotoxicity [8].
7 This PDF is for personal use only. To obtain commercial reprints,
8 This PDF is for personal use only. To obtain commercial reprints,
TDF Renal Dysfunction
TDF Renal Dysfunction Sarala Naicker MBChB, FRCP, PhD Division of Nephrology Dept of Internal Medicine University of the Witwatersrand Johannesburg South Africa SA HIV Clinician Society Conference Cape
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationDisclaimer. Presenter Release are for reactive use by Medical Information only internal learning/educational use only
Disclaimer Presenter Release are for reactive use by Medical Information only internal learning/educational use only Any unsolicited request from HCP must be forwarded to Medical Information Housekeeping
More informationSimilar Risk of Renal Events Among Patients Treated With Tenofovir or Entecavir for Chronic Hepatitis B
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:941 946 Similar Risk of Renal Events Among Patients Treated With Tenofovir or Entecavir for Chronic Hepatitis B ROBERT G. GISH,* MARGARET D. CLARK, STEVE
More informationSafety Profile of Viread and Truvada. Ian McGowan, MD PhD FRCP Cape Town MTN Regional Meeting September, 2008
Safety Profile of Viread and Truvada Ian McGowan, MD PhD FRCP Cape Town MTN Regional Meeting September, 2008 Overview Safety assessment in drug development Physiology 101 Renal Bone Liver Safety profile
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationManagement of Hepatitis B - Information for primary care providers
Management of Hepatitis B - Information for primary care providers July 2018 Chronic hepatitis B (CHB) is often a lifelong condition. Not everyone infected needs anti-viral therapy. This document outlines
More informationOptimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy. Watcharasak Chotiyaputta
Optimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy Watcharasak Chotiyaputta Progression of Liver Disease Goal of HBV Treatment: prevention the development of cirrhosis
More informationManagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance
anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance / 김강모 연수강좌 anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance 김강모 울산대학교의과대학서울아산병원소화기내과
More informationManagement of HBV in KidneyTransplanted Patients Dr.E.Nemati
Management of HBV in KidneyTransplanted Patients Dr.E.Nemati Hepatitis B virus (HBV) infection Hepatitis B virus (HBV) infection confers a significantly negative impact on the clinical outcomes of kidney
More informationManagement of Decompensated Chronic Hepatitis B
Management of Decompensated Chronic Hepatitis B Dr James YY Fung, FRACP, MD Department of Medicine The University of Hong Kong Liver Transplant Center Queen Mary Hospital State Key Laboratory for Liver
More informationEmtricitabine / Tenofovir disoproxil Stada 200 mg/245 mg film-coated tablets , Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Emtricitabine / Tenofovir disoproxil Stada 200 mg/245 mg film-coated tablets 30.5.2016, Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a public summary Emtricitabine / Tenofovir
More informationEU-Risk Management Plan for Emtricitabine/Tenofovir (NL/H/3635/001/DC and NL/H/3636/001/DC) V1.3
VI.2 Elements for a public summary 200 mg/245 mg film-coated tablets VI.2.1 Overview of disease epidemiology HIV-1 infection In this decade, the global prevalence of HIV-1 infection stabilized
More informationRenal safety of tenofovir containing antiretroviral regimen in a Singapore cohort
Chua et al. AIDS Research and Therapy 2012, 9:19 SHORT REPORT Open Access Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort Arlene C Chua 1*, Ryan M Llorin 1, Kelvin Lai
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationCLINICAL PEARLS OF NEW HIV MEDICATIONS PHARMACIST OBJECTIVES TECHNICIAN OBJECTIVES. At the end of this presentation pharmacists will be able to:
CLINICAL PEARLS OF NEW HIV MEDICATIONS Cindy Lou Zoellner, PharmD, BCPS Added Qualifications in Infectious Diseases Senior Clinical Pharmacy Specialist in HIV Parkland Health & Hospital System Volunteer
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationNovedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona
Novedades en el tratamiento de la hepatitis B: noticias desde la EASL Maria Buti Hospital Universitario Valle Hebrón Barcelona Milestones in CHB treatment Conventional IFN 1991 Lamivudine (LAM) 1998 Adefovir
More informationChronic Hepatitis B: management update.
Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationTenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases
pissn 2287-2728 eissn 2287-285X Case Report Clinical and Molecular Hepatology 2016;22:286-291 Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases Hyeki Cho 1, Yuri Cho 1,
More informationNational Institute for Health and Clinical Excellence. Tenofovir disoproxil fumarate for the treatment of hepatitis B
National Institute for Health and Clinical Excellence Tenofovir disoproxil fumarate for the treatment of hepatitis B Comment 1: The draft remit Comments received on the draft scope Appropriateness As liver
More informationTenofovir disoproxil STADA 245 mg film-coated tablets , Version 1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Tenofovir disoproxil STADA 245 mg film-coated tablets 9.3.2016, Version 1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology HIV-1 infection
More informationUpdate on HBV Treatment
Update on HBV Treatment Calvin Q. Pan MD, FAASLD, FACG, MACP Professor of Medicine Division of Gastroenterology and Hepatology Department of Medicine, NYU Langone Health New York University School of Medicine,
More informationHBV Therapy in Special Populations: Liver Cirrhosis
HBV Therapy in Special Populations: Liver Cirrhosis Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationHepatitis B Case Studies
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Hepatitis B Case Studies Nina Kim, MD MSc Associate Professor of Medicine University of Washington Harborview Madison Clinic and Hepatitis & Liver Clinic No
More informationLandmarks for Prevention and Treatment
HBeAg-positive chronic hepatitis B Why do I treat my patient with a nucleos(t)ide analogue? Dr. Nancy Leung BSc(Lon) MSc(Lon) MBBS(Lon) MD(Lon), FRCP(Lon) FRCP(Edin) FHKCP FHKAM Consultant Physician, Alice
More informationHorizon Scanning Technology Summary. Tenofovir disoproxil fumarate for hepatitis B. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Tenofovir disoproxil fumarate for hepatitis B April 2007 This technology summary is based on information available at the time of research
More informationNUCs for Chronic Hepatitis B. Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona.
NUCs for Chronic Hepatitis B Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona. Spain Disclosures Advisory board of, and/or, received speaker fee from
More informationOur better understanding of the natural
TREATMENT OF CHRONIC HEPATITIS B: MASTERING THE BASICS ON A COMPLEX TOPIC Ke-Qin Hu, MD* ABSTRACT The availability of newer antiviral agents, as well as comprehensive treatment recommendations, has equipped
More informationtenofovir disoproxil (as fumarate), 245mg, film-coated tablet (Viread ) SMC No. (720/11) Gilead Sciences Ltd
tenofovir disoproxil (as fumarate), 245mg, film-coated tablet (Viread ) SMC No. (720/11) Gilead Sciences Ltd 05 August 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationCurrently status of HBV therapy: efficacy and limitations
9 November 2016 Currently status of HBV therapy: efficacy and limitations Pietro Lampertico Gastroenterology and Hepatology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico University of
More informationTenofovir as a drug of choice for the chronic hepatitis B treatment
EASL endorsed conference White Nights of Hepatology 2013 Symposium Perspectives of chronic viral hepatitis B and C treatment June 6-7 Saint-Petersburg Tenofovir as a drug of choice for the chronic hepatitis
More informationOptions for HBV treatments in case of TDF toxicity
Options for HBV treatments in case of TDF toxicity Pr Corinne Isnard Bagnis Pitie Salpetriere Hospital corinne.bagnis@psl.aphp.fr Honorarium from Novartis BMS Gilead Abbvie GSK Roche Research funding BMS
More informationNephrotoxicity caused by oral antiviral agents in patients with chronic hepatitis B treated in a hospital for tropical diseases in Thailand
Thu et al. BMC Pharmacology and Toxicology (2015) 16:38 DOI 10.1186/s40360-015-0037-6 RESEARCH ARTICLE Open Access Nephrotoxicity caused by oral antiviral agents in patients with chronic hepatitis B treated
More informationHepatitis B Treatment Pearls. Agenda
Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,
More informationTreatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia
Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute
More informationImportant Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP)
Important Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) For Healthcare Providers About Emtricitabine/Tenofovir Disoproxil
More informationentecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd
entecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd 09 December 2011 The Scottish Medicines Consortium (SMC) has
More informationHepatitis B. Epidemiology and Natural History and Implications for Treatment
Hepatitis B Epidemiology and Natural History and Implications for Treatment Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco
More informationEffects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis
Gut and Liver, Vol. 11, No. 6, November 2017, pp. 828-834 ORiginal Article Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated
More informationHepatitis B: Future treatment developments
Hepatitis B: Future treatment developments VIII International Update Workshop in Hepatology Curitiba, 27.08.2016 Christoph Sarrazin St. Josefs-Hospital Wiesbaden and Goethe-University, Frankfurt am Main
More informationHBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But
HBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But Hospital Universitario Valle Hebron and Ciberehd del Insttuto Carlos III. Barcelona. Spain Disclosures Advisory board of,
More informationHBV Diagnosis and Treatment
HBV Diagnosis and Treatment Anna S. F. Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor, MI, USA
More informationDoes Viral Cure Prevent HCC Development
Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,
More informationESCMID Online Lecture Library. by author
Pro-Con: To stop or not to stop hepatitis B treatment? To Stop HBV Treatment Resat Ozaras, MD, Professor Istanbul University, Cerrahpasa Medical School, Infection Dept. HBV Therapy Nucleos(t)ide analogues
More informationRenal safety of tenofovir in HIV-infected patients who switch from stavudine or zidovudine to tenofovir
Original Article Vol. 29 No. 3 Renal safety of tenofovir:- Wiwattanathum P & Sungkanuparph S. 113 Renal safety of tenofovir in HIV-infected patients who switch from stavudine or zidovudine to tenofovir
More informationChronic hepatitis B - New goals, new treatment. New England Journal Of Medicine, 2008, v. 359 n. 23, p
Title Chronic hepatitis B - New goals, new treatment Author(s) Lai, CL; Yuen, MF Citation New England Journal Of Medicine, 2008, v. 359 n. 23, p. 2488-2491 Issued Date 2008 URL http://hdl.handle.net/10722/59270
More informationIs there a need for combination therapy? No. Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain
Is there a need for combination therapy? No Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain No, No and No EASL Update HBV Guidelines 2012 The most potent drugs with the optimal
More informationChronic Hepatitis B - Antiviral Resistance in Korea -
Chronic Hepatitis B - Antiviral Resistance in Korea - Young-Suk Lim University of Ulsan College of Medicine Asan Medical Center Seoul, Korea HBV Genome partially double-stranded DNA genome about 3200 nucleotides
More informationHow to treat HCV-HBV co-infection?
How to treat HCV-HBV co-infection? Robert Flisiak Department of Infectious Diseases and Hepatology Medical University of Białymstoku Paris Hepatology Conference, 14-15 january 219 Conflict od interest
More informationChronic HBV Management in 2013
Chronic HBV Management in 2013 Mohammad Hossein Somi MD Professor of Gastroentrology and hepatology Liver and Gastrointestinal Disease Research Center Tabriz University of Medical Sciences 1 HBV in 2013
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis B Drug: Baraclude (entecavir), Epivir (lamivudine), Hepsera (adefovir), Intron A (interferon alfa- 2b), Pegasys (peginterferon alfa-2a), Tyzeka (telbivudine),
More informationHepatitis B Prior Authorization Policy
Hepatitis B Prior Authorization Policy Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review of medical literature,
More informationReal Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,
More informationChoice of Oral Drug for Hepatitis B: Status Asokananda Konar
Choice of Oral Drug for Hepatitis B: Status 2011 Asokananda Konar Chronic hepatitis B (CHB) is a global public health challenge with an estimated 350 to 400 million people with chronic HBV infection, despite
More informationClinical Case. Christophe Hézode, Henri Mondor Hospital, Paris-Est University, Créteil, France
Clinical Case Christophe Hézode, Henri Mondor Hospital, Paris-Est University, Créteil, France Paris, January 16th 2018 Links of interest and Disclaimer Adviser, speaker, investigator for: Abbvie, BMS,
More informationHBeAg-negative chronic hepatitis B. with a nucleos(t)ide analogue?
4 th PARIS HEPATITIS CONFERENCE HBeAg-negative chronic hepatitis B Why do I treat my chronic hepatitis B patients with a nucleos(t)ide analogue? George V. Papatheodoridis, MD 2nd Department of Internal
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationHBV, HCV, HIV and Kidney Transplantation. Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania
HBV, HCV, HIV and Kidney Transplantation Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania Objectives Prevalence of hepatitis B (HBV), hepatitis C (HCV) and human immunodeficiency
More informationRecent achievements in the treatment of hepatitis B by nucleosides and nucleotides. K. Zhdanov
EASL endorsed conference White Nights of Hepatology 2012 Adverse events during antiviral therapy: how to predict, manage and monitor June 7-8 Saint-Petersburg Recent achievements in the treatment of hepatitis
More informationEmtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) Training Guide for Healthcare Providers
Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) Training Guide for Healthcare Providers About emtricitabine/tenofovir disoproxil fumarate for HIV-1 PrEP
More informationCOMPETING INTEREST OF FINANCIAL VALUE
BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Dr Ian Williams University College London Medical School COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Ian Williams
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tyzeka) Reference Number: CP.CPA.164 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationA Message to Presenters
A Message to Presenters As a healthcare professional speaking on behalf of Bristol-Myers Squibb (BMS), any presentation you make on our behalf must be consistent with the current FDA-approved product labeling
More informationVemlidy. (tenofovir alafenamide) New Product Slideshow
Vemlidy (tenofovir alafenamide) New Product Slideshow Introduction Brand name: Vemlidy Generic name: Tenofovir alafenamide Pharmacological class: Nucleoside analogue (reverse transcriptase inhibitor) Strength
More information1. Introduction. Bangkok 10400, Thailand. Correspondence should be addressed to Abhasnee Sobhonslidsuk;
Gastroenterology Research and Practice Volume 2016, Article ID 2952635, 7 pages http://dx.doi.org/10.1155/2016/2952635 Research Article Nucleotide Analogue-Related Proximal Renal Tubular Dysfunction during
More informationEntecavir Maintains a High Genetic Barrier to HBV Resistance Through 6 Years in Naïve Patients
Entecavir Maintains a High Genetic Barrier to HBV Resistance Through 6 Years in Naïve Patients D.J. Tenney 1, K.A. Pokorowski 1, R.E. Rose 1, C.J. Baldick 1, B.J. Eggers 1, J. Fang 1, M.J. Wichroski 1,
More informationTreatment of chronic hepatitis B: Evolution over two decades_
doi:10.1111/j.1440-1746.2010.06545.x REVIEW Treatment of chronic hepatitis B: Evolution over two decades_6545 138..143 Man-Fung Yuen and Ching-Lung Lai Department of Medicine, the University of Hong Kong,
More informationHepatitis B and D Update on clinical aspects
Hepatitis B and D Update on clinical aspects B. Müllhaupt Gastroenterology and Hepatology Swiss Transplant and HPB-Center University Hospital Zurich beat.muellhaupt@usz.ch B.M. 11.11.17 Hepatitis Strategy
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More informationAn Update HBV Treatment
An Update HBV Treatment Epidemiology Natural history Treatment Daryl T.-Y. Lau, MD, MPH Associate Professor of Medicine Director of Translational Liver Research Division of Gastroenterology BIDMC, Harvard
More informationEmerging Drug List ADEFOVIR DIPIVOXIL FOR HEPATITIS B VIRUS INFECTION NO. 48 SEPTEMBER Generic (Trade Name): Adefovir dipivoxil (Hepsera TM )
Generic (Trade Name): Manufacturer: Adefovir dipivoxil (Hepsera TM ) Gilead Sciences, Inc. NO. 48 SEPTEMBER 2003 Indication: Current Regulatory Status: For the treatment of adults showing evidence of active
More informationClinical Policy: Hepatitis B Drugs Reference Number: AZ.CP.PHAR.03 Effective Date: Last Review Date: Line of Business: Arizona Medicaid
Clinical Policy: Reference Number: AZ.CP.PHAR.03 Effective Date: 11.16.16 Last Review Date: 08.18 Line of Business: Arizona Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationFor now, do not stop NUCs PHC R. PARANÁ Federal University of Bahia, Brazil HUPES-University Hospital Gastro-Hepatology Unit
For now, do not stop NUCs PHC 2019 R. PARANÁ Federal University of Bahia, Brazil HUPES-University Hospital Gastro-Hepatology Unit Disclosure PI: Clinical Trials -ABBVIE -INTERCEPT -GILEAD -Novartis -BMS
More informationStribild, a Single Tablet Regimen for the Treatment of HIV Disease
Comb Prod Ther (2013) 3:1 8 DOI 10.1007/s13556-013-0001-y REVIEW Stribild, a Single Tablet Regimen for the Treatment of HIV Disease Cynthia Brinson To view enhanced content go to www.combitherapy-open.com
More informationOverview of disease epidemiology
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology HIV-1 infection In this decade, the global prevalence of HIV-1 infection stabilized at 0.8%. However, the overall number of people
More informationAcute Hepatitis B Virus Infection with Recovery
Hepatitis B: Clear as Mud Melissa Osborn, MD, MSCR Assistant Professor Emory University School of Medicine Atlanta, GA 1 Objectives 1. Distinguish the various stages in the natural history of chronic hepatitis
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationMarch 29, :15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D
March 29, 2017 12:15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D Provided by #IM2017 This lunch symposium is not part of the official Internal Medicine Meeting 2017 Education Program. #IM2017
More informationDifferences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir (TDF)-treated Adults in ESS40006
13th Conference on Retroviruses and Opportunistic Infections Denver, CO, USA. February 5-9, 2006 Poster Number 777 Differences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir
More informationHow to use pegylated Interferon for Chronic Hepatitis B in 2015
How to use pegylated Interferon for Chronic Hepatitis B in 215 Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University, Thailand ASIAN-PACIFIC CLINICAL PRACTICE
More informationHepatitis C Medications Prior Authorization Criteria
Hepatitis C Medications Authorization Criteria Epclusa (/velpatasvir), Harvoni (ledipasvir/), Sovaldi (), Daklinza (daclatasvir), Zepatier (elbasvir/grazoprevir), Olysio (simeprevir), Viekira Pak (ombitasvir/paritaprevir/ritonavir;
More informationSwiss Summary of the Risk Management Plan (RMP) for. Vosevi, film-coated tablets
Swiss Summary of the Management Plan (RMP) for, film-coated tablets (Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination) 400mg/100mg/100mg Version 1.0 (February 2018) final Based on EU RMP version
More informationSummary of the risk management plan (RMP) for Rezolsta (darunavir / cobicistat)
EMA/608280/2014 Summary of the risk management plan (RMP) for Rezolsta (darunavir / cobicistat) This is a summary of the risk management plan (RMP) for Rezolsta, which details the measures to be taken
More informationCurrent Status of HBV and Liver Transplant
Current Status of HBV and Liver HBV as Indication for Liver ation in U.S. Significant decrease in rate of wait listing for decompensated cirrhosis since 2003 (since s) No change in rate of wait listing
More informationClinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents
Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents 1 Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in
More informationOutline. Updates in the Clinical Management of Hepatitis B and C. Who should be screened for HBV? Chronic Hepatitis B 10/7/2018
Outline Updates in the Clinical Management of Hepatitis B and C Jennifer C. Lai, MD, MBA Transplant Hepatologist Associate Professor of Medicine In Residence University of California, San Francisco Initial
More informationThe advent of sensitive assays for the detection of hepatitis
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2013;-:1 10 All studies published in Clinical Gastroenterology and Hepatology are embargoed until 3PM ET of the day they are published as corrected proofs on-line.
More informationHEPATITIS B: WHO AND WHEN TO TREAT?
HEPATITIS B: WHO AND WHEN TO TREAT? George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department of
More informationSpontaneous resolution of de novo hepatitis B after living donor liver transplantation with hepatitis B core antibody positive graft: a case report
Hara et al. Surgical Case Reports (2016) 2:118 DOI 10.1186/s40792-016-0246-2 CASE REPORT Open Access Spontaneous resolution of de novo hepatitis B after living donor liver transplantation with hepatitis
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationHepatitis B Diagnosis and Management. Marion Peters University of California San Francisco
Hepatitis B Diagnosis and Management Marion Peters University of California San Francisco COI Spouse works for Hoffmann-La Roche HBV is a life long, dynamic disease Changes over time Risk of end stage
More informationA Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B
Curr Hepatitis Rep (2010) 9:75 90 DOI 10.1007/s11901-010-0039-1 A Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B Vandana Khungar & Steven-Huy
More informationBasics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology
Basics of hepatitis B diagnostics Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Background Epidemiology Morphology Life-cycle Diagnostic markers
More informationRE: NDA # Truvada (emtricitabine and tenofovir disoproxil fumarate) Tablets MACMIS # 18360
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Joyce Q. Acbay Director, Regulatory Affairs 333 Lakeside Drive
More informationImportant Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. For Healthcare Providers
Important Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication For Healthcare Providers About TRUVADA for a PrEP Indication INDICATION AND PRESCRIBING CONSIDERATIONS TRUVADA,
More information